SEC Filing Summary: Predictive Oncology Inc. (POAI)
Business Context and Reporting Period
This Form 8-K was filed on November 22, 2024, by Predictive Oncology Inc. (POAI), a Delaware corporation listed on the NASDAQ Capital Market. The report addresses a regulatory notice received on November 20, 2024, regarding compliance with continued listing standards.
Key Financial Metrics
The filing references the Company's most recent financial position as reported in its Form 10-Q for the quarter ended September 30, 2024:
- Stockholders' Equity: $1,966,969
- Required Minimum Equity: $2,500,000 (per Nasdaq Listing Rule 5550(b)(1))
- Alternative Compliance Standards: The Company did not meet the alternative standards of having a market value of listed securities of at least $35 million or net income from continuing operations of $500,000 in the most recent fiscal year or two of the last three fiscal years.
The filing text does not provide specific values for revenue, profit, cash flow, margins, or debt levels beyond the equity figure cited.
Material Changes and Regulatory Status
The Company received a formal Notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC stating it is not in compliance with the minimum stockholders' equity requirement. While the Notice has no immediate effect on the listing, the Company's continued listing is contingent upon regaining compliance.
Outlook, Management Commentary, and Risks
Compliance Timeline:
- Plan Submission Deadline: The Company has 45 calendar days from November 20, 2024, to submit a compliance plan to Nasdaq (deadline: January 6, 2025).
- Extension Possibility: If a plan is accepted, Nasdaq may grant an extension of up to 180 calendar days to evidence compliance.
Management Action: The Company is evaluating various courses of action to regain compliance and intends to submit a plan timely.
Risks and Contingencies:
- There is no assurance that the Company's plan will be accepted or that it will successfully regain compliance.
- Failure to submit a plan, have it accepted, or regain compliance within the extension period could result in delisting.
- The Company retains the right to appeal a delisting determination to a Nasdaq Hearings Panel, which would stay the delisting action pending the hearing, though success is not guaranteed.
Key Facts for Investor Verification
- Verify the Company's current stockholders' equity and whether it has increased since the September 30, 2024, reporting date.
- Monitor the submission of the compliance plan to Nasdaq by the January 6, 2025, deadline.
- Review the Company's proposed strategy for raising equity or meeting alternative compliance standards (market value or net income).
- Check for any subsequent announcements regarding the acceptance of the compliance plan or the granting of an extension.